EHang Holdings Ltd - ADR vs Nuvalent Inc — how do they compare? EHang Holdings Ltd - ADR trades at $5.44 (market cap $414.87M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 23.6× EHang Holdings Ltd - ADR's market cap, and Nuvalent Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| EH | NUVL | |
|---|---|---|
Market Cap | $414.87M | $9.81B |
Sector | Industrials | Technology |
52-Week High | $19.99 | $123.96 |
52-Week Low | $5.41 | $72.16 |
Enterprise Value | $354.54M | $8.52B |
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $5.56, up 2.02% on the day, amid mixed technical and fundamental signals. The stock shows a bearish technical trend with oversold short-term RSI, while fundamentally, the company reported Q1 2026 revenue of $418M, flat year-over-year but sharply lower sequentially due to delivery timing. The company remains unprofitable with a net margin of -77.56% and negative ROE of -34.03%, though it maintains a strong cash position of $1.12B and recently announced a $30M share repurchase program.
The outlook is bifurcated between significant long-term potential in the advanced air mobility market and near-term execution and profitability challenges. Investment opportunity lies in the company's first-mover technology and global regulatory progress, but risks include persistent cash burn, high valuation multiples despite losses, and intense competition in the emerging eVTOL sector. Analyst consensus is divided with a $6.97 price target but equal buy/hold/sell ratings.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Trailing returns across standard periods
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →